No profile data available.
Prelude Therapeutics Incorporated (PRLD) is a healthcare company in the additional cancer treatment drugs industry, based in Wilmington, United States, with about 79 full-time employees.
It reported revenue of $12.14 million for fiscal year 2025, up 73.4% from fiscal year 2024, and net income of -$99.50 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $5.70 million. Its market capitalization was $309.82 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients.
Prelude Therapeutics reported $12.14 million in revenue for fiscal year 2025, up 73.4% from $7.00 million in fiscal year 2024. In Q2 2026 revenue was $5.70 million.
$309.82 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Artiva Biotherapeutics, Inc. (ARTV), Indaptus Therapeutics, Inc. (INDP), Allogene Therapeutics, Inc. (ALLO), Perspective Therapeutics, Inc. (CATX).